



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/986,630	11/19/01	SUE ET AL.	TM&K 0014

EXAMINER	
ROBERT SELLERS	
ART UNIT	PAPER NUMBER
1712	5

DATE MAILED:

EXAMINER INTERVIEW SUMMARY RECORD

All participants (applicant, applicant's representative, PTO personnel):

- (1) Robert Sellers (3) _____
(2) Jeong-Uwe Szipl (4) _____

Date of interview April 2, 2003

Type: ☐ Telephonic ☒ Personal (copy is given to ☐ applicant ☐ applicant's representative)

Exhibit shown or demonstration conducted: ☒ Yes ☐ No. If yes, brief description: Amendment filed July 18, 2001
in parent application no. 09/319,487 (after allowance, not entered).

Agreement ☒ was reached with respect to some or all of the claims in question. ☐ was not reached.

Claims discussed: 23-28

Identification of prior art discussed: ~~the~~ Indian Journal of Technology article by Hassan et al.

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: Independent claims
23 and 26 wherein "m" of general formula (I) has been limited to zero
avoids a potential double patenting issue with parent U.S. Patent No 6,329,492
(m is a positive number). The last two lines of the claims limits Ar' to the 1 and 3
positions in the cyclopentane ring, thereby overcoming Hassan et al. The cancellation of

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

☒ 1. It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph below has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW (e.g., items 1-7 on the reverse side of this form). If a response to the last Office action has already been filed, then applicant is given one month from this interview date to provide a statement of the substance of the interview.

☐ 2. Since the examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the substance of the interview unless box 1 above is also checked.

Examiner's Signature

Art Unit: 1712

Claims 1-5, 10, 15, 16, 19 and 20 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 6,329,492 (the patent of parent application no. 09/319,487).

Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the application are identical to those of the patent except for the limitation that "when m represents 0, Ar¹ groups are present in the 1 and 3 positions of the cyclopentane ring (independent claims 1, 3 and 5)."

Independent claims 1, 3 and 5 of the application set forth general formula (I) wherein m is a positive number which is encompassed by independent claims 1, 3, 5, 6 and 10 of the patent.

Claims 6 and 23-28 require the arylcyclopentyl repeating unit of general formula (I) quantified by "m" to be zero which is a distinct invention from general formula (I) of the claims of U.S. Patent No. 6,329,492 wherein "m" is confined to a positive number.


The closest prior art embodied in the Indian Journal of Technology article by Hassan et al. shows a 4,4'-cyclopentylidene bisphenol diglycidyl ether which is precluded by the claimed requirement that the Ar¹ groups be present in the 1 and 3 positions of the cyclopentane ring.

Art Unit: 1712

Claim 6 differs from independent claims 23 and 26 in that the arylcyclopentylaryl polyepoxide is depicted by general formula (II) wherein the arylcyclopentyl repeating unit quantified by "m" in general formula (I) of claims 23 and 26 is not present. The X¹ group of Ar¹ in general formula (II) of claim 6 includes a hydroxyl group which is not defined in claims 23 and 26.

Claim 23 is directed to the compound of a cooligomer represented by general formula (I). Claim 26 is drawn to "[a]n epoxy resin molding material for encapsulating electronic devices" comprising a compound of general formula (I).

(703) 308-2399 (Fax no. (703) 872-9310)
Monday to Friday from 9:30 to 6:00 EST



Robert Sellers
Primary Examiner
Art Unit 1712

rs
4/25/03